Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer.

被引：0
|
作者：
Li, Jian
Huang, Jing
Ba, Yi
Cao, Baoshan
Luo, Suxia
Li, Wenhua
Song, Zhengbo
Zhu, Liangjun
Xiong, Jianping
An, Guangyu
Zhang, Yanqiao
Li, Zhihua
Li, Yongsheng
Gu, Yanhong
Li, Xingya
Huang, Chenghui
Fu, Qihan
Hu, Changlu
Shen, Lin
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Med Oncol,Canc Hosp, Beijing, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[4] Peking Univ Third Hosp, Canc Chemotherapy & Radiat Dept, Beijing, Peoples R China
[5] Zhengzhou Univ, Henan Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[6] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Dept Gastrointestinal Med Oncol, Shanghai, Peoples R China
[7] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[8] Jiangsu Canc Hosp, Nanjing, Peoples R China
[9] Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China
[10] Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China
[11] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[12] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[13] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China
[14] Jiangsu Prov Hosp, Nanjing, Peoples R China
[15] Zhengzhou Univ, Affiliated Hosp 1, Oncol Dept, Zhengzhou, Peoples R China
[16] Cent South Univ, Xiangya Hosp 3, Changsha, Peoples R China
[17] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[18] Anhui Prov Canc Hosp, Ward Med Oncol 4, Hefei, Peoples R China
[19] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.191
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：191 / 191
页数：1
相关论文
共 50 条
  • [1] Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors.
    Li, Jian
    Shen, Lin
    Gu, Yanhong
    Calles, Antonio
    Wu, Lin
    Ba, Yi
    Li, Zhi-hua
    Bai, Chunmei
    Yao, Yu
    Hubert, Ayala
    Perez, Julia Martinez
    Zugazagoitia, Jon
    Ding, Yuli
    Liu, Sumei
    Rao, Zhiyue
    He, Zhiwen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 604 - 604
  • [2] Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.
    Zhao, Jun
    Fang, Jian
    Yu, Yan
    Chu, Qian
    Li, Xiaoyan
    Chen, Jiayan
    Liu, Zhe
    Zhang, Li
    Wu, Lin
    Zhuang, Wu
    Li, XingYa
    Zhao, Yanqiu
    Xing, Ligang
    Liu, Lian
    Bai, Chunmei
    Dong, Xiaorong
    Song, Qibin
    Pan, Pinghua
    Fang, Xuefeng
    Wang, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
    Shi, Yuankai
    Fang, Jian
    Xing, Ligang
    Yao, Yu
    Zhang, Jian
    Liu, Lian
    Wang, Yongsheng
    Hu, Changlu
    Xiong, Jianping
    Liu, Zhihua
    Yang, Runxiang
    Wang, Zhen
    Zhao, Enfeng
    Wang, Mengzhao
    Zhao, Yanqiu
    Tang, Kejing
    Li, Zhihua
    Song, Zhengbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (36_SUPPL) : 468214 - 468214
  • [4] Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
    Kuboki, Y.
    Yaeger, R.
    Fakih, M.
    Strickler, J. H.
    Masuishi, T.
    Kim, E. J-H.
    Bestvina, C. M.
    Langer, C. J.
    Krauss, J. C.
    Puri, S.
    Cardona, P.
    Chang, E. K.
    Tran, Q.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1445 - S1446
  • [5] Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
    Kuboki, Y.
    Yaeger, R.
    Fakih, M. G.
    Strickler, J. H.
    Masuishi, T.
    Kim, E. J.
    Bestvina, C. M.
    Langer, C. J.
    Krauss, J. C.
    Puri, S.
    Cardona, P.
    Chan, E.
    Tran, Q.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S680 - S681
  • [6] Investigation of KRAS G12C inhibitor JAB-21822 as a single agent and in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models
    Wang, P.
    Zheng, Q.
    Kang, D.
    Sun, X.
    Zhu, S.
    Wang, Y.
    Long, W.
    Lin, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1441 - S1441
  • [7] Assessing the safety profile of sotorasib in KRAS G12C-mutated advanced NSCLC
    Reactions Weekly, 2025, 2045 (1) : 6 - 6
  • [8] CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC
    Clarke, J. M.
    Felip, E.
    Li, B. T.
    Ruffinelli, J. C.
    Garrido, P.
    Zugazagoitia, J.
    Goldberg, S. B.
    Ramalingam, S. S.
    Victoria, I.
    Puri, S.
    Gandara, D. R.
    Varrieur, T.
    Edmonds, S.
    Palmer, K.
    Snyder, W.
    Govindan, R.
    Rybkin, I.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S118 - S119
  • [9] Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer
    Milner-Watts, Charlotte
    O'Sullivan, Hazel
    Stewart, James
    Idaikkadar, Praveena
    Tokaca, Nadza
    Davidson, Michael
    Yousaf, Nadia
    Bhosle, Jaishree
    Popat, Sanjay
    O'Brien, Mary
    Minchom, Anna
    LUNG CANCER, 2023, 178 : S31 - S32
  • [10] Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study
    Xu, R-H.
    Xu, Y.
    Yan, D.
    Munster, P.
    Ruan, D.
    Deng, Y.
    Pan, H.
    Underhill, C. R.
    Richardson, G.
    Nordman, I.
    Lee, K-W.
    Wei, S.
    Li, X.
    Shan, J.
    Han, G.
    Henderson, S.
    Xie, X.
    Xiang, Z.
    Shi, Z.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S410 - S411
12345